<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649801</url>
  </required_header>
  <id_info>
    <org_study_id>HDZ_ER002_CS</org_study_id>
    <nct_id>NCT04649801</nct_id>
  </id_info>
  <brief_title>Catheter Ablation for Atrial Fibrillation in patientS With End-sTage Heart Failure and Eligibility for Heart Transplantation</brief_title>
  <acronym>CASTLE-HTx</acronym>
  <official_title>Catheter Ablation for Atrial Fibrillation in patientS With End-sTage Heart Failure and Eligibility for Heart Transplantation (CASTLE-HTx)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart and Diabetes Center North-Rhine Westfalia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart and Diabetes Center North-Rhine Westfalia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CASTLE-HTx will determine if AF ablation has beneficial effects on mortality in patients with&#xD;
      end stage HF who are eligible for HTx&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CASTLE-HTx is a randomized evaluation of ablative treatment of AF in patients with severe&#xD;
      left ventricular dysfunction who are candidates and eligible for HTx. The primary endpoint is&#xD;
      the composite of all-cause mortality, worsening of HF requiring a high urgent transplantation&#xD;
      or LVAD implantation. The secondary study endpoints are all-cause mortality, cardiovascular&#xD;
      mortality, cerebrovascular accidents, worsening of HF requiring unplanned hospitalization, AF&#xD;
      burden reduction, unplanned hospitalization due to cardiovascular reason, all-cause&#xD;
      hospitalization, QoL, number of delivered implantable cardioverter-defibrillator (ICD)&#xD;
      therapies, time to first ICD therapy, number of device-detected ventricular&#xD;
      tachycardia/ventricular fibrillation episodes, LV function, exercise tolerance, and&#xD;
      percentage of right ventricular pacing. Ventricular myocardial tissue will be obtained from&#xD;
      patients who will undergo LVAD implantation or HTx to assess the effect of catheter ablation&#xD;
      on human HF myocardium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality or transplantation</measure>
    <time_frame>24 months</time_frame>
    <description>composite of all-cause mortality, worsening of HF requiring a high urgent transplantation or implantation of a ventricular assist device</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>conventional</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>interventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrial fibrillation ablation</intervention_name>
    <description>Catheter ablation</description>
    <arm_group_label>interventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic paroxysmal or persistent AF (paroxysmal: ≥2 symptomatic or one documented&#xD;
             AF episode lasting 30 seconds or more in the last 3 months; persistent: ≥1 documented&#xD;
             episode in the last 3 months).&#xD;
&#xD;
          2. Eligible for heart transplantation due to end-stage heart failure&#xD;
&#xD;
          3. LV dysfunction with left ventricular ejection fraction ≤ 35% (measured in the last 6&#xD;
             weeks prior to enrollment).&#xD;
&#xD;
          4. NYHA class ≥ II.&#xD;
&#xD;
          5. Indication for ICD therapy due to primary prevention.&#xD;
&#xD;
          6. Dual chamber ICD with Home Monitoring capabilities already implanted.&#xD;
&#xD;
          7. The patient is willing and able to comply with the protocol and has provided written&#xD;
             informed consent.&#xD;
&#xD;
          8. Sufficient GPRS-network coverage in the patient's area.&#xD;
&#xD;
          9. Age ≥ 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented left atrial diameter &gt; 6 cm (parasternal long-axis view)&#xD;
&#xD;
          2. Contraindication for chronic anticoagulation therapy or heparin&#xD;
&#xD;
          3. Previous left heart ablation procedure for atrial fibrillation&#xD;
&#xD;
          4. Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular accident&#xD;
             within 2 months prior to enrollment&#xD;
&#xD;
          5. Untreated hypothyroidism or hyperthyroidism&#xD;
&#xD;
          6. Enrollment in another investigational drug or device study&#xD;
&#xD;
          7. Indication for cardiac resynchronization therapy&#xD;
&#xD;
          8. Woman currently pregnant, breastfeeding, or not using reliable contraceptive measures&#xD;
             during fertility age&#xD;
&#xD;
          9. Mental or physical inability to participate in the study&#xD;
&#xD;
         10. Listed as &quot;high urgent&quot; for heart transplantation&#xD;
&#xD;
         11. Cardiac assist device implanted&#xD;
&#xD;
         12. Planned cardiovascular intervention&#xD;
&#xD;
         13. Life expectancy ≤ 12 month&#xD;
&#xD;
         14. Uncontrolled hypertension&#xD;
&#xD;
         15. Requirement for dialysis due to end-stage renal failure&#xD;
&#xD;
         16. Participation in another telemonitoring concept&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Sohns, MD</last_name>
    <phone>49 5731 971327</phone>
    <email>csohns@hdz-nrw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Astrid Kleemeyer</last_name>
    <phone>49 5731 971258</phone>
    <email>akleemeyer@hdz-nrw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid R Kleemeyer</last_name>
      <phone>+49495731971258</phone>
      <email>akleemeyer@hdz-nrw.de</email>
    </contact>
    <investigator>
      <last_name>Christian Sohns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

